​Principal Investigator: Dr. Royce Lee

​Disease: PTSD

Research Description: Post-traumatic stress disorder (PTSD) can be a debilitating neuropsychiatric condition. Experienced by 8% of the general US population over their lifetime, at-risk populations (such as those exposed to community violence or warfare) have nearly double the risk. Currently approved PTSD treatments help only 1 in 5 achieve remission – more options are needed. Published evidence indicates that an ADHD medication (mixed amphetamine salt, known as Adderall) has restorative, prosocial effects that may allow people with PTSD to restore their connection to family and their social support, improving outcomes. This randomized, double-blind Phase IIA trial is testing mixed amphetamine salt to improve PTSD symptoms and improve social connections among veterans and adult survivors of community violence. If effective, this research could not only better the quality of life for PTSD patients by improving social relationships but also improve outcomes of existing PTSD therapies, especially cognitive behavioral therapy.

Funding Partners: The Searle Funds at The Chicago Community Trust, the David and Susie Sherman Philanthropic Fund and others

Initial CWR Funding Role: Primary